Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11184288 | 0.87 | — | — | |
| SCHEMBL3388566 | 0.87 | — | — | |
| SCHEMBL28830462 | 0.84 | — | — | |
| SCHEMBL4929206 | 0.84 | LMNA (0.48) | TRPV1TRPA1 | |
| SCHEMBL28563966 | 0.84 | TRPV1 (0.36) | TRPV1TRPA1 | |
| SCHEMBL8459228 | 0.84 | TRPV1 (0.31) | TRPV1TRPA1 | |
| SCHEMBL8453338 | 0.84 | TRPV1 (0.31) | TRPV1TRPA1 | |
| SCHEMBL11163355 | 0.84 | TRPV1 (0.31) | TRPV1TRPA1 | |
| SCHEMBL8403266 | 0.84 | — | — | |
| SCHEMBL1565831 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245003-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | claimed |
| EP-0513300-B1 | QUATERNARY CROSSLINKED ALLYLAMMONIUMPOLYMERS, PREPARATION AND USE THEREOF | ZENECA LTD (GB) | 1997-05-14 | — | — | EP | claimed |
| US-5589166-A | Cross-linked quaternary ammonium derivatives of poly(N,N-dialkylallyl) ammonium polymers | ZENECA LIMITED (GB) | 1996-12-31 | — | — | US | claimed |
| EP-0740679-A1 | CROSSLINKED POLYMERIC AMMONIUM SALTS | E.I. DU PONT DE NEMOURS & COMPANY INCORPORATED (US) | 1996-11-06 | — | — | EP | claimed |
| US-5556619-A | BILE ACID SEQUESTERANTS TO LOWER BLOOD CHOLESTEROL, POLYAMINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-17 | — | — | US | claimed |
| WO-1995019384-A1 | CROSSLINKED POLYMERIC AMMONIUM SALTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-07-20 | — | — | WO | claimed |
| EP-0513300-A1 | QUATERNARY CROSSLINKED ALLYLAMMONIUMPOLYMERS, PREPARATION AND USE THEREOF. | ICI PLC (GB) | 1992-11-19 | — | — | EP | claimed |
| WO-1992010522-A1 | QUATERNARY CROSSLINKED ALLYLAMMONIUMPOLYMERS, PREPARATION AND USE THEREOF | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-06-25 | — | — | WO | claimed |
| US-8535642-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2013-09-17 | — | — | US | disclosed |
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | disclosed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | disclosed |
| EP-2245003-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010060941-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-06-03 | — | — | WO | disclosed |
| EP-0582324-A1 | Heat transfer sheet | DAI NIPPON INSATSU KABUSHIKI KAISHA (JP) | 1994-02-09 | — | — | EP | disclosed |
| US-5223476-A | HEAT TRANSFER SHEET | DAI NIPPON INSATSU KABUSHIKI KAISHA (JP) | 1993-06-29 | — | — | US | disclosed |
| EP-0513300-A1 | QUATERNARY CROSSLINKED ALLYLAMMONIUMPOLYMERS, PREPARATION AND USE THEREOF. | ICI PLC (GB) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992010522-A1 | QUATERNARY CROSSLINKED ALLYLAMMONIUMPOLYMERS, PREPARATION AND USE THEREOF | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| US-5106815-A | Heat transfer sheet | DAI NIPPON INSATSU KABUSHIKI KAISHA (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0427867-A1 | THERMAL TRANSFER SHEET | DAI NIPPON INSATSU KABUSHIKI KAISHA (JP) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | C5, TXN, CBR3 | TRPV1 2122/4885TRPA1 762/4885 |
| US-20110052504-A1 | CONTRAST AGENTS | C5, TXN, CBR3 | TRPV1 2122/4885TRPA1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.